申请人:Pfizer Inc.
公开号:US05130334A1
公开(公告)日:1992-07-14
Novel 5-alkanesulphonamido-2-[N-(alkanesulphonamidoheterocyclicmethyl)-N-methyla mino]indane compounds have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzofused heteroclyclic group derived from either benzofuran or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. The most preferred member compound is 5-methanesulphonamido-2-[N-(5-methanesulphonamidobenzofur-2-ylmethyl)-N-me thylamino]indane. Methods for preparing these compounds from known starting materials are provided.
已经制备了新型的Novel 5-烷基磺酰胺基-2-[N-(烷基磺酰胺杂环甲基)-N-甲基氨基]茚烷化合物,包括它们的药学上可接受的盐和各种关键的新型中间体。这些化合物中存在的杂环基团是源自苯并呋喃或喹啉的苯并杂环基团,并且通过可用的环碳原子连接到分子相邻的甲基基团上,该环碳原子位于杂原子的α位。这些化合物在治疗中作为抗心律失常剂是有用的,因此在治疗各种心脏心律失常方面具有价值。最优选的成员化合物是5-甲烷磺酰胺基-2-[N-(5-甲烷磺酰胺基苯并呋喃-2-基甲基)-N-甲基氨基]茚烷。提供了从已知起始材料制备这些化合物的方法。